In vitro inhibition of monkeypox virus production and spread by Interferon-β
In vitro inhibition of monkeypox virus production and spread by Interferon-β
复制标题
DOI：
10.1186/1743-422x-9-5
复制
发表时间：
2012-01-06
期刊：
影响因子：
4.8
通讯作者：
Hensley, Lisa E.
中科院分区：
文献类型：
--
作者：
Johnston, Sara C.;Lin, Kenny L.;Hensley, Lisa E.
背景资料：正痘病毒属包含许多能够在人类中引起疾病的病毒物种，包括天花病毒（天花的病原体）、猴痘病毒、牛痘病毒和牛痘病毒（该属的原型成员）。猴痘是一种人畜共患疾病，在刚果民主共和国流行，其特征是全身病变发展和显著的淋巴结病。像天花病毒，猴痘病毒是一个高优先级的病原体治疗发展，由于其潜在的人畜共患病，意外或故意引入到一个天真的population.Results后，造成严重的疾病，具有显着的健康影响：本研究的目的是调查的预防和治疗潜力的干扰素-β（IFN-β）用于对猴痘病毒。我们发现用人IFN-β治疗可显著降低猴痘病毒的产生和体外传播。IFN-β在感染后6-8小时引入时基本上抑制猴痘病毒，揭示了其用作治疗剂的潜力。IFN-β诱导的抗病毒蛋白MxA在感染的细胞中的表达，和组成性表达的MxA被证明抑制猴痘病毒infection.Conclusions：我们的研究结果表明，成功地抑制猴痘病毒使用人IFN-β，并表明，IFN-β可能作为一种新的安全的治疗人类猴痘病。
Background: The Orthopoxvirus genus contains numerous virus species that are capable of causing disease in humans, including variola virus (the etiological agent of smallpox), monkeypox virus, cowpox virus, and vaccinia virus (the prototypical member of the genus). Monkeypox is a zoonotic disease that is endemic in the Democratic Republic of the Congo and is characterized by systemic lesion development and prominent lymphadenopathy. Like variola virus, monkeypox virus is a high priority pathogen for therapeutic development due to its potential to cause serious disease with significant health impacts after zoonotic, accidental, or deliberate introduction into a naive population.Results: The purpose of this study was to investigate the prophylactic and therapeutic potential of interferon-beta (IFN-beta) for use against monkeypox virus. We found that treatment with human IFN-beta results in a significant decrease in monkeypox virus production and spread in vitro. IFN-beta substantially inhibited monkeypox virus when introduced 6-8 h post infection, revealing its potential for use as a therapeutic. IFN-beta induced the expression of the antiviral protein MxA in infected cells, and constitutive expression of MxA was shown to inhibit monkeypox virus infection.Conclusions: Our results demonstrate the successful inhibition of monkeypox virus using human IFN-beta and suggest that IFN-beta could potentially serve as a novel safe therapeutic for human monkeypox disease.